It can inhibit response to amyloid plaques and its deletion leads to protection in the mouse model of Alzheimer disease (AD) [29] and in humans some CD33 genetic variants are associated with late-onset AD [30]; its potential role in pathology of TBEV might be associated with its regulatory role in inflammatory responses. Here, CD33 is linked to early-onset autosomal dominant Alzheimer disease.